The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
LOS ANGELES, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TruVivoTM, a pioneering all-human 2D+ hepatic system that supports ADME/DMPK, toxicology and disease modeling applications, has been selected as the Cell ...
The overall safety profile of melphalan/HDS was comparable among relevant subgroups, with an absence of cumulative toxicity in successive treatment cycles. Treatment with melphalan delivered via a ...
69 weeks (16 months) median hPFS in patients with uveal melanoma. 38 weeks (8.5 months) median hPFS in patients with cholangiocarcinoma. Importance of Repeated Treatments: The investigators’ approach ...
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver ...
Melphalan/HDS treatment for patients with hepatic dominant metastatic uveal melanoma: Results from an expanded access program.
Hepatic nerves have an underexplored role in liver function. The global prevalence of liver disease has reached unprecedented levels, with over 1.6 billion individuals affected by metabolic ...
Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results